The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst like Robyn Karnauskas from Truist Securities could lead to increased investor confidence in Regeneron Pharmaceuticals. This endorsement is likely to have a positive impact on the stock price in the short term as it suggests the analyst's belief in the company's potential for growth and value.